Literature DB >> 20851132

Effects of pantoprazole in experimental acute pancreatitis.

Thilo Hackert1, Stefan Tudor, Klaus Felix, Dmitry Dovshanskiy, Werner Hartwig, Wolfgang A Simon, Jens Werner.   

Abstract

AIMS: Oxidative stress with free radicals plays a crucial role in acute pancreatitis (AP). Pantoprazole (PPZ), widely used as a proton pump inhibitor, possesses reactivity towards hydroxyl radicals. The aim of the study was to examine the effect of PPZ on the course of experimental AP. MAIN
METHODS: Mild AP was induced in rats by caerulein (n=12). Severe AP was induced by infusion of glycodeoxycholic acid (10mM) into the pancreatic duct combined with caerulein (n=12). Both AP models were randomized to PPZ treatment (20mg/kg at baseline and after 12h) or placebo. Control animals received Ringer solution (n=6) without AP induction. After 24h severity of AP was examined by histology, enzyme levels, edema and inflammatory markers (myeloperoxidase, protein profiling). Furthermore, CD62P and CD31 for leukocyte and platelet activation were investigated. KEY
FINDINGS: Histology showed that PPZ treatment reduced tissue infiltration of inflammatory cells and acinar cell necrosis in severe AP. After PPZ treatment CD62P expression in mild AP and CD31 expression in severe pancreatitis decreased, indicating an inhibition of platelet activation. In mild and severe AP, PPZ significantly decreased amylase, LDH, edema and myeloperoxidase activity. Protein profile of pancreatic juice and serum revealed different spectra and less pancreatic juice proteins in PPZ treated groups indicating less acinar cell leakage. SIGNIFICANCE: PPZ possesses anti-inflammatory in vivo properties and attenuates the course of AP. This is mediated via a reduced expression of inflammatory and adhesive proteins with a consecutive decrease in platelet and leukocyte activation as key steps in the pathogenesis of AP.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851132     DOI: 10.1016/j.lfs.2010.09.008

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Research Into the Effect of Proton Pump Inhibitors on Lungs and Leukocytes.

Authors:  Orhan Ozatık; Fikriye Yasemin Ozatık; Yasemin Teksen; Ilknur Dag; Suna Saygılı; Ahmet Koçak
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

Review 2.  Pancreatitis in cats.

Authors:  P Jane Armstrong; David A Williams
Journal:  Top Companion Anim Med       Date:  2012-08

3.  Preventive and therapeutic significance of octreotide combined with lansoprazole on post-ERCP pancreatitis and its effect on serum amylase, inflammatory factors and immune function.

Authors:  Zhiliang Chen; Hong Fu; Jianfeng Fang; Jianhui Yang; Xin Zhu; Bingxiang Cheng; Tiannv Ding
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

4.  Effectiveness and safety of proton pump inhibitors for treating acute pancreatitis: A protocol for systematic review and meta analysis.

Authors:  Tao Cheng; Bo-Fu Liu; Tian-Yong Han; Zhi-Han Gu; Pan Pan; Haifang Yu
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

5.  Proton Pump Inhibitors Were Associated With Reduced Pseudocysts in Acute Pancreatitis: A Multicenter Cohort Study.

Authors:  Shengyu Zhang; Ziying Han; Yuelun Zhang; Xiaomao Gao; Shicheng Zheng; Ruifeng Wang; Dong Wu
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

7.  ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Authors:  Stanley L Marks; Peter H Kook; Mark G Papich; M K Tolbert; Michael D Willard
Journal:  J Vet Intern Med       Date:  2018-10-31       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.